David Happel - 06 Feb 2025 Form 4 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role: President & CEO, Director
Signature: /s/ Elizabeth Rozek, Attorney-in-Fact
Issuer symbol: SGMT
Transactions as of: 06 Feb 2025
Net transactions value: $0
Form type: 4
Filing time: 07 Feb 2025, 16:43:56 UTC
Previous filing: 28 Mar 2024
Next filing: 23 Jul 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SGMT	Series A Common Stock	Award	$0	+116,000	+18%	$0.000000	755,200	06 Feb 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SGMT	Stock Option (Right to Buy)	Award	$0	+472,000		$0.000000	472,000	06 Feb 2025	Series A Common Stock	472,000	$4.71	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.
F2	The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date.